Luye Pharma Group Ltd.
LYPHF
Price:
$0.3094
Market Cap:
$1.16B
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; F...[Read more]
Industry
Drug Manufacturers - General
IPO Date
2021-02-18
Stock Exchange
PNK
Ticker
LYPHF
PE Ratio
[15.47]
ROE
[1.00%]
Current Ratio
[1.32]
Dividend Yield
[0%]
Enterprise Value
[3.93B]
Dividend History
The ROE as of November 2024 (TTM) for Luye Pharma Group Ltd. (LYPHF) is 1.00%
According to Luye Pharma Group Ltd.’s latest financial reports and current stock price. The company's current ROE is 1.00%. This represents a change of 549.24% compared to the average of 0.15% of the last 4 quarters.
Luye Pharma Group Ltd. (LYPHF) Historical ROE (quarterly & annually)
How has LYPHF ROE performed in the past?
The mean historical ROE of Luye Pharma Group Ltd. over the last ten years is 10.42%. The current 1.00% ROE has changed -90.45% with respect to the historical average. Over the past ten years (40 quarters), LYPHF's ROE was at its highest in in the June 2010 quarter at 4.57%. The ROE was at its lowest in in the March 2009 quarter at 0%.
Average
10.42%
Median
12.83%
Minimum
-1.58%
Maximum
16.69%
Luye Pharma Group Ltd. (LYPHF) ROE by Quarter and Year
Discovering the peaks and valleys of Luye Pharma Group Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 15.12%
Maximum Annual ROE = 16.69%
Minimum Annual Increase = -475.39%
Minimum Annual ROE = -1.58%
| Year | ROE | Change |
|---|---|---|
| 2023 | 4.25% | -28.49% |
| 2022 | 5.94% | -475.39% |
| 2021 | -1.58% | -117.68% |
| 2020 | 8.95% | -43.76% |
| 2019 | 15.92% | -4.62% |
| 2018 | 16.69% | 15.12% |
| 2017 | 14.50% | 4.55% |
| 2016 | 13.87% | 4.11% |
| 2015 | 13.32% | 7.97% |
| 2014 | 12.34% | -29.70% |
Luye Pharma Group Ltd. (LYPHF) Average ROE
How has LYPHF ROE performed in the past?
The current ROE of Luye Pharma Group Ltd. (LYPHF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
2.87%
5-year avg
6.70%
10-year avg
10.42%
Luye Pharma Group Ltd. (LYPHF) ROE vs. Peers
How is LYPHF’s ROE compared to its peers?
Luye Pharma Group Ltd.’s ROE is less than Astellas Pharma Inc. (1.08%), less than Sanofi (10.71%), greater than Amarin Corporation plc (-7.22%), less than Novartis AG (41.08%), less than Scilex Holding Company (64.26%), less than Biogen Inc. (10.25%), less than Gilead Sciences, Inc. (5.21%), less than AstraZeneca PLC (16.80%), less than Johnson & Johnson (20.94%), greater than Bristol-Myers Squibb Company (-36.26%), less than AbbVie Inc. (55.02%), less than Eli Lilly and Company (65.15%), less than Pfizer Inc. (4.72%), less than Merck & Co., Inc. (29.85%),
| Company | ROE | Market cap |
|---|---|---|
| 1.08% | $20.93B | |
| 10.71% | $132.76B | |
| -7.22% | $248.69M | |
| 41.08% | $216.23B | |
| 64.26% | $186.31M | |
| 10.25% | $25.29B | |
| 5.21% | $111.85B | |
| 16.80% | $221.47B | |
| 20.94% | $380.98B | |
| -36.26% | $112.46B | |
| 55.02% | $354.10B | |
| 65.15% | $765.28B | |
| 4.72% | $157.31B | |
| 29.85% | $258.22B |
Build a custom stock screener for Luye Pharma Group Ltd. (LYPHF) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Luye Pharma Group Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Luye Pharma Group Ltd. (LYPHF) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Luye Pharma Group Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Luye Pharma Group Ltd.'s ROE?
How is the ROE calculated for Luye Pharma Group Ltd. (LYPHF)?
What is the highest ROE for Luye Pharma Group Ltd. (LYPHF)?
What is the 3-year average ROE for Luye Pharma Group Ltd. (LYPHF)?
What is the 5-year average ROE for Luye Pharma Group Ltd. (LYPHF)?
How does the current ROE for Luye Pharma Group Ltd. (LYPHF) compare to its historical average?